Endothelial lipase (EL) is a major negative regulator of plasma high density lipoprotein (HDL) levels in mice, rabbits, and most probably, humans. Although this regulatory function is critically dependent on EL's hydrolysis of HDL phospholipids, as yet there is no phospholipase assay specific for EL in plasma. We have developed such an assay for the mouse enzyme using a commercially available phospholipid-like fluorescent substrate in combination with an EL neutralizing antibody. The specificity of the assay was established using EL knockout mice and its utility demonstrated by detection of an increase in plasma EL phospholipase activity following exposure of wild type mice to lipopolysaccharide. The assay revealed that murine pre-heparin plasma does not contain measurable EL activity, indicating that the hydrolysis of HDL phospholipids by EL in vivo likely occurs on the cell surface. 
MATERIALS & METHODS

Materials and Reagents:
The EnzChek Phospholipase A1 Assay Kit containing the PED-A1 substrate and the fluorescent standard 4,4-Difluoro-5,7-Dimethyl-4-Bora-3a,4a-Diaza-s-Indacene-3-Pentanoic Acid, abbreviation BODIPY-C5) were purchased from Invitrogen. The liposomes, which were prepared according to the kit's instructions, contained dioleoylphosphatidylcholine: dioleoylphosphatidylglycerol: PED-A1 in the ratio 5:5:1. The liposomes were stable for at least 3 months. Other reagents, including heparin (Cat. No. H-1027) and LPS (Cat. No. L4391) were obtained from Sigma-Aldrich, St. Louis, MO unless otherwise stated. 4-20% polyacrylamide pre-cast gels were obtained from Pierce (Rockford, Il). The anti-EL polyclonal and control antibodies were generated and IgG was purified using a protein A affinity column as previously reported (3).
PLA1 assay: A typical assay was carried out at 37 o C for 30 minutes in a 96-well round bottom clear plate (Costar) with 0.5 μl of mouse plasma or indicated amounts of a stated enzyme and 16 μm PED-A1 which was either, a), formulated in liposomes with the total assay volume adjusted to 100 μl with water or, b), solubilized in DMSO to a total assay volume of 100 μl. The Spectramax M2 plate reader from MDS Analytical Technologies was used for fluorescent measurements. The software Softmax Pro 5 was used for data collection and analysis. The maximum excitation /emission (Ex/Em) wavelengths for PED-A1 were determined to be 485/538 nm with a 515 nm filter cutoff. The upper and lower detection limits for BODIPY-C5 using this assay and instrument are 2.4 μmole/well and 0.1 pmole/well, respectively. EL PLA1 activity: PLA1 activity was measured using 0.5 μl of plasma incubated with control IgG antibody (final concentration 30 μg/ml) or anti-EL inhibitory antibody (final concentration 30 μg/ml) for 5 minutes on ice prior to the PLA1 assay. At this concentration, the neutralizing antibody showed saturation. The EL PLA1 activity was calculated as the difference between the two measurements.
Thin layer chromatography: Plasma samples (1 μl) or 1 unit of snake venom PLA1 enzyme were incubated with liposomes for 30 minutes at 37 o C and lipids were extracted using a total volume of 750 μl of chloroform and methanol (2:1), dried down and dissolved in 50 μl of chloroform. Samples were run on a silica gel plate for 10 minutes with a solvent system comprising chloroform: methanol : 20% ammonium hydroxide in the ratio 14:6:1. Fluorescent bands on the plate were detected using a DyNA Light™ UV transilluminator (302 nm, Fisher Scientific, Pittsburgh, PA).
Adenoviruses: A recombinant adenoviral vector expressing murine EL (AdmEL) and a control virus (Ad-GFP) were prepared as described previously (3).
Animal experiments: Age and gender matched C57BL/6 mice were used for the following experiments. All procedures were conducted in conformity with the United States Public Health Service Policy on Humane Care and Use of Laboratory Animals and approved by the Institutional Animal Care and Use Committee of the State University of New York Downstate Medical Center. Adenovirus was administered intravenously (i.v.) at a dose of 10 11 viral particles diluted in PBS on day 0 of the each experiment. The plasma collected 5 minutes after i.v. heparin administration on day 3 post-transduction with Ad-mEL is referred to as "EL plasma" (see Results Section). The "EL plasma" had a stable EL activity for at least one year when stored at -70 o C. For murine EL overexpression studies, mice were pre-bled, heparin was injected i.v. at 300 units heparin per kg body weight and the mice were bled again at indicated intervals. For LPS studies, 20 μg (1 mg/kg of body weight) of LPS or PBS were injected per mouse intraperitoneally (i.p.) and post-heparin plasma was obtained after 16 hours.
Mouse plasma: Blood was drawn in heparinized microcapillary tubes from the retro-orbital plexus at indicated time points before and after i.v. or i.p. injection of 300 units heparin per kg body weight. Blood was centrifuged at 10,000 rcf for 10 min at 4 o C and plasma was separated and used for the analysis and/or stored at -70 o C. Pre-and postheparin plasma from EL knockout mice were kindly provided by Dr. Daniel J. Rader, University of Pennsylvania.
Western blotting: SDS-PAGE and immunoblotting analysis of murine EL were carried out as described previously (16) . One μl of mouse plasma was added to sample loading buffer and β-mercaptoethanol, and held at 70 o C for 10 minutes before electrophoresis. The anti-EL serum was used at 1:2500 dilution, the secondary HRP-conjugated goat antirabbit IgG (Jackson Immunoresearch) at 1:5000 dilution and detection was carried out using the SuperSignal West Pico Chemiluminescent Substrate (Pierce).
Data Analysis
The relative fluorescence intensity of the unquenched BODIPY-C5 fatty acid standard was used to calculate the initial velocity of enzymatic reactions producing this molecule as nmole/min/ml plasma. The initial velocities were calculated based on the linear increase in product over the time in this PLA1 assay, usually 0-15 minutes at the 16 μM of PED-A1 substrate concentration. The rate of hydrolysis as determined from the continuous increase in fluorescence intensity was equal to the rate of separation of the sn-1 fatty acid product from the PED-A1 substrate. Rates were presented as the mean +/-the SD of three determinations. The results from two sets of conditions were analyzed by either paired or unpaired Student's t tests; p<0.05 was considered to be statistically significant.
Results:
Optimizing conditions for the use of the PED-A1 substrate in the assay of EL in plasma:
A new fluorogenic phospholipid substrate, PED-A1 (Invitrogen), was recently reported for the measurement of the PLA1 activity of purified EL, or of EL in conditioned medium (23) . The glycerophosphoethanolamine substrate has a BODIPY fluor added at the sn-1 position, an alkyl chain with an ether bond that is resistant to esterase activity at the sn-2 position and a quencher, Dabcyl, at the sn-3 position (23) . It is thus a PLA1-specific substrate, producing a continuous fluorescence increase as the modified fatty acid at the sn-1 position is separated from the quencher at sn-3 position (23) . The published PED-A1 assay cannot measure EL activity in the presence of plasma (23) . We hypothesized that proper presentation of the PED-A1substrate to the EL enzyme is required for determining EL activity in the mouse plasma.
Since the active dimer of EL is attached to the endothelial cell surface via reversible binding to heparan sulfate proteoglycans (27) , a bolus of heparin administered intravenously was used to release EL into the plasma compartment; this method is routine for LPL and HL activity measurements (28) . The 5 minute post-heparin plasma from murine EL-overexpressing mice (referred to as "EL plasma") was collected and used for optimization of assay conditions. The presence of elevated full length murine EL protein in the "EL plasma" was confirmed by Western blotting using an antibody specific for murine EL (Fig. 1A) . In a TG assay (29) , the "EL plasma" had higher activity than wild type (WT) post-heparin plasma (51±0.5 versus 25±0.3 μmole/min/ml plasma), confirming the presence of active EL in the "EL plasma".
PED-A1 and its fluorescent hydrolysis product were separated by thin layer chromatography and visualized using a UV transilluminator (Fig. 1B) . The intact substrate is shown in lane 1. When hydrolyzed by a positive control enzyme, commercially available snake venom PLA1, most of the PED-A1 substrate was converted to a slower moving band (Lane 5), the location of which matches that of the sn-1 BODIPY fatty acid standard (lane 2). Post-heparin "EL plasma" also acted on the substrate to generate a product at this location (lane 4). Thus, EL plasma contains a PLA1 activity acting on the PED-A1 substrate.
Since EL acts at the water/lipoprotein surface of HDL, we reasoned that presenting the PED-A1 substrate incorporated into liposomes would mimic the phospholipid presentation in HDL particles. The ability of EL in the "EL plasma" to hydrolyze PED-A1 was compared in two conditions: in the presence of DMSO, used in test tube assays by Connelly's group (23) , and in a liposome format. As shown in Fig 1C, the "EL plasma" hydrolyzed PED-A1 with a greater initial velocity and a linear response that extended over a longer time in liposomes than in DMSO, indicating that PED-A1 is a better substrate presented in liposomes. PED-A1 formulated in liposomes was used in all subsequent assays.
To characterize the EL activity with the PED-A1 substrate, initial velocity was determined using a fixed amount of "EL plasma" (0.01 μl per well) and increasing amounts of PED-A1 (Fig. 1D) . The rates were proportional to substrate concentration under the conditions used. No appreciable PLA1 activity was detected using the same amount (0.01 μl) of post-heparin plasma from control WT mice, indicating that endogenous PLA1 activity is very low compared to that of overexpressed EL. The intraassay co-efficiency variation was 4.7%.
To determine the upper limit of the enzyme concentration range where the initial rate was proportional to enzyme concentration, initial velocity was determined using 16 μM PED-A1 and increasing amounts of the "EL plasma" (Fig. 1E ). With this substrate concentration, increase in the initial velocity was linear to 0.04 μl of "EL plasma" per 100 μl assay solution (Fig. 1E ).
An early report noted that the fluorescent phospholipid analog PED6 was a poor substrate for EL in the test-tube (23) . Consistent with this, "EL plasma" showed much less activity with this analog, whether or not it was presented in the liposome format (Fig.  1F) . Thus, of the two substrates, PED-A1 is preferred for assaying mouse plasma EL enzymatic activity. It has the additional advantage that it does not allow complications from the hydrolytic activity of plasma PLA2 enzymes (30) .
Use of the assay to study the fate of EL in mouse plasma after heparin administration:
The same mouse EL overexpression system was used to study the fate of EL released into the bloodstream by heparin. There was no difference in PLA1 activity in the pre-heparin plasma samples from control mice and in mice where EL was overexpressed in the liver by adenoviral-mediated transduction (2.1 versus 2.2 nmole/mim/ml, P>0.05). This was the case despite Western blotting detection of a doublet of 40 kDa bands from the cleaved N-terminal region of the EL protein in pre-heparin plasma of EL-transduced mice that is missing in mice transduced with GFP ( Fig. 2A, compare lanes 1 and 2) . Therefore, very little active EL is released into the plasma in this model in the absence of heparin, and the N-terminal domain is not active in vivo.
Five minutes after the heparin injection, the EL activity in the plasma of ELtransduced mice increased to 4.7 fold the preheparin level. This activity then slowly decreased and was still above baseline level 30 minutes after injection (Fig. 2B) . The amount of the full-length EL protein in these mice increased and decreased in parallel (Fig 2A) .
Intraperitoneal (i.p.) heparin administration is much easier than i.v. injection in mice and has been used to release endothelial bound lipases (31) . We therefore compared its effectiveness to that of i.v. injection. Plasma EL activity increased more slowly, to 2.9 fold the basal level, at 30 minutes after i.p.administration, and remained above baseline level at 60 minutes (Fig. 2D) . As with the i.v. injections, plasma changes in EL full length protein amounts followed changes in activity (Fig. 2C) .
Of note, in both Figures 2A and 2C , immediately after heparin administration , compared with pre-heparin samples, there were visible increased amounts of the closelyspaced N-terminal domain cleavage products of EL, indicating a rapid cleavage of the full-length EL once released by heparin into the plasma. This is in agreement with our previous observation that EL is cleaved in the extracellular compartment (16) .
In summary, these data confirm that i.v. injection of heparin is more effective in releasing EL from the cell surface than i.p. injection and that plasma collected at 5 minutes after i.v. heparin injection contains the highest EL activity.
The endogenous EL activity in the post-heparin plasma of WT mice:
We carried out experiments in WT mice similar to those described above in ELoverexpressing mice to study total endogenous post-heparin PLA1 activity (Figs. 3 A and  B) . Significantly higher total PLA1 activity was observed in post-heparin relative to pre-heparin WT plasma after either intravenous or intraperitoneal heparin injection. The latter approach, using 30 minute post-heparin plasma, yielded a smaller increase in PLA1 activity compared to i.v. injection using 5 minute post-heparin plasma (Figs. 3 A and B , 15% versus 30%). Thus endogenous EL behaves similarly to ectopic EL in its response to these two methods of heparin administration. The intra-assay co-efficiency variation was 4.0%.
Since active EL is released from the cell surface into the blood stream upon heparin treatment, we hypothesized that EL would be the major contributor to the difference in pre-and post-heparin total PLA1 activities that is apparent in Figure 3A . To test this, the pre-and post-heparin plasma samples from EL knockout (KO) mice were collected and the total PLA1 activities measured. In support of this hypothesis, there was no significant difference in plasma PLA1 activity between the pre-and post-heparin plasma samples from EL KO mice (Fig. 3C) .
Extending the assay for use in post-heparin plasma:
To separate the EL PLA1 activity from the total PLA1 activity in a post-heparin plasma sample, an EL neutralizing antibody was added to post-heparin plasma prior to the assay to inhibit plasma EL activity (3). There was significant inhibition of postheparin PLA1 activity using the neutralizing antibody compared to the activity using a control antibody (n=5, p<0.05, Fig. 4A ), establishing the ability of the neutralizing antibody to inhibit EL phospholipase A1 activity in post-heparin plasma samples. No EL phospholipase A1 activity was detected in the pre-heparin plasma when the results with the two antibodies were compared (2.24±0.11 versus 2.28±0.09 nmol/min/ml plasma), confirming that active endogenous EL is not present in the pre-heparin plasma. The antibody did not inhibit PLA1 activity in the post-heparin plasma samples from EL KO mice (Fig. 4B) , validating the specificity of the anti-EL antibody.
Thus, measurement of the specific phospholipase activity of endogenous EL in mouse plasma following heparin treatment can be accomplished using a PLA1 assay with the substrate PED-A1 incorporated into liposomes and the assay carried out on a single post-heparin plasma sample in the presence and absence of the EL-neutralizing antibody.
LPS treatment and EL activity:
Acute inflammation induced by LPS has been shown to increase EL mRNA and protein expression in various tissues in culture, including macrophages and endothelial cells from humans and mice (32) (33) . We hypothesized that LPS treatment in vivo in mice would increase post-heparin plasma EL activity. We found, using the single post-heparin sample PLA1 assay with the neutralizing antibody, that overnight treatment of mice with LPS increased post-heparin EL activity about 2.0 fold (Fig. 5) . This result supports a role for EL in the regulation of plasma HDL levels during the acute phase response (34) .
Discussion:
Using a newly described phospholipid-like fluorescent substrate in combination with an EL neutralizing antibody, we have determined EL PLA1 activity in the postheparin plasma of mice. The specificity of this approach was validated using post-heparin samples from EL KO mice. The ability of the assay to measure plasma EL activity was demonstrated in measurements on plasma from WT mice treated with LPS, known to induce EL expression in endothelial cells, macrophages and a variety of tissues. In addition, using the pre-and post-heparin samples approach, we provided a dynamic view of the turnover of EL in plasma after heparin treatment.
We found that pre-heparin plasma does not contain measurable EL activity, a property also exhibited by LPL (28) . The absence of pre-heparin plasma EL activity could be due to the relatively high affinity of EL for heparan sulfate proteoglycans, to fast inactivation of any released enzyme by proteolytical cleavage and/or to inhibition of activity by the inhibitor angiopoietin-like protein-3. Because there is no active EL enzyme in the non-heparinized plasma, the hydrolysis of HDL phospholipids by EL in vivo likely occurs on the cell surface, in a manner similar to the interaction between LPL and TG-rich particles. This local interaction of EL and HDL may affect local cellular cholesterol and fatty acid uptake as well as signal transduction through peroxisome proliferator-activated receptors (35) .
In contrast to our previous report that EL does not significantly contribute to the TG lipase activity present in the post-heparin plasma (29), despite exhibiting a low level of TG lipase activity when the purified enzyme is assayed in the test tube (much lower than an equivalent amount of LPL), our data (Fig. 4) demonstrate that EL does contribute to the significant PLA1 activity present in the post-heparin plasma. This provides direct evidence that EL in vivo functions as a phospholipase. The result is consistent with the elevated levels of plasma phospholipids, but not plasma TGs, in EL KO mice compared with WT controls (2, 4) . Thus in combination with use of the TG lipase assay (29), we are able to differentiate among the enzymatic activities of HL, EL and LPL in postheparin plasma of mice.
As indicated above, the increase in PLA1 activity in post-heparin versus preheparin plasma is most likely due to the release of active EL from the cell surface (Fig.  4) . However, we still do not know which enzyme(s) besides HL are responsible for the PLA1 activity in the pre-heparin samples. This "pre-existing" PLA1 activity could be altered when heparin is added. For example, ANGPTL3 is released from the cell surface into plasma by heparin (36) , and it is an endogenous inhibitor of HL (37) . Also, additional HL is released by heparin in mice (38) . Therefore, plasma EL activity cannot be reliably measured by calculating the difference between post-and pre-heparin activities (data not shown). Instead, comparison of the PLA1 activities of a single postheparin plasma sample which is pretreated with control antibody or anti-EL antibody, avoiding interference by HL and possibly other factors, is the preferred method of assessing plasma EL activity.
We recognize that our current assay has some limitations. The performance of the assay could be improved by increasing the substrate concentration. The assay can be used only for EL activity in mouse plasma, not that of humans, since the inactivating antibody does not neutralize human EL activity. To differentiate EL phospholipase activity from that of other phospholipases in human post-heparin plasma, we are developing a neutralizing antibody for human EL activity.
The experiments showing the changes in the protein and PLA1 activity of EL in plasma with time following release by heparin provided a snapshot of global EL activity but did not give information regarding tissue or cellular levels. Since the BODIPY labeled fatty acid, after lipase mediated hydrolysis of the PED-A1 substrate, can enter cells and be incorporated into cellular lipids, the self-quenched PED-A1 substrate has been used for monitoring EL-mediated fatty acid uptake in cell culture (23) . We plan to investigate whether PED-A1 can be used as a functional probe for tissue EL activity in vivo.
In summary, we have developed a homogeneous PLA1 assay employing the ELneutralizing antibody for the determination of murine post-heparin plasma EL phospholipase A1 activity. This is the first such assay which is effective for EL in plasma. Armed with this assay, researchers will be able to screen for the efficacy of new potential inhibitors of EL in mice and study proteins with EL-regulating properties. 
